211 related articles for article (PubMed ID: 37944531)
1. Personalized drug screening in patient-derived organoids of biliary tract cancer and its clinical application.
Ren X; Huang M; Weng W; Xie Y; Wu Y; Zhu S; Zhang Y; Li D; Lai J; Shen S; Lin J; Kuang M; Li X; Yu J; Xu L
Cell Rep Med; 2023 Nov; 4(11):101277. PubMed ID: 37944531
[TBL] [Abstract][Full Text] [Related]
2. The potential of patient-derived organoids in precision medicine of biliary tract cancer.
Yáñez-Bartolomé M; Macarulla T; Tian TV
Cell Rep Med; 2023 Nov; 4(11):101294. PubMed ID: 37992681
[TBL] [Abstract][Full Text] [Related]
3. Human equilibrative nucleoside transporter 1 (hENT1) expression as a predictive biomarker for gemcitabine chemotherapy in biliary tract cancer.
Kim J; Kim H; Lee JC; Kim JW; Paik WH; Lee SH; Hwang JH; Ryu JK; Kim YT
PLoS One; 2018; 13(12):e0209104. PubMed ID: 30557411
[TBL] [Abstract][Full Text] [Related]
4. Establishment of Patient-Derived Organoids and Drug Screening for Biliary Tract Carcinoma.
Saito Y; Muramatsu T; Kanai Y; Ojima H; Sukeda A; Hiraoka N; Arai E; Sugiyama Y; Matsuzaki J; Uchida R; Yoshikawa N; Furukawa R; Saito H
Cell Rep; 2019 Apr; 27(4):1265-1276.e4. PubMed ID: 31018139
[TBL] [Abstract][Full Text] [Related]
5. Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing.
Zu M; Hao X; Ning J; Zhou X; Gong Y; Lang Y; Xu W; Zhang J; Ding S
Biomed Pharmacother; 2023 Jul; 163():114751. PubMed ID: 37105073
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic KRAS-expressing organoids with biliary epithelial stem cell properties give rise to biliary tract cancer in mice.
Kasuga A; Semba T; Sato R; Nobusue H; Sugihara E; Takaishi H; Kanai T; Saya H; Arima Y
Cancer Sci; 2021 May; 112(5):1822-1838. PubMed ID: 33068050
[TBL] [Abstract][Full Text] [Related]
7. Genomic characteristics and drug screening among organoids derived from non-small cell lung cancer patients.
Chen JH; Chu XP; Zhang JT; Nie Q; Tang WF; Su J; Yan HH; Zheng HP; Chen ZX; Chen X; Song MM; Yi X; Li PS; Guan YF; Li G; Deng CX; Rosell R; Wu YL; Zhong WZ
Thorac Cancer; 2020 Aug; 11(8):2279-2290. PubMed ID: 32633046
[TBL] [Abstract][Full Text] [Related]
8. Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models.
Peraldo-Neia C; Cavalloni G; Soster M; Gammaitoni L; Marchiò S; Sassi F; Trusolino L; Bertotti A; Medico E; Capussotti L; Aglietta M; Leone F
BMC Cancer; 2014 Dec; 14():918. PubMed ID: 25479910
[TBL] [Abstract][Full Text] [Related]
9. Gastric cancer patient-derived organoids model for the therapeutic drug screening.
Xu J; Gong J; Li M; Kang Y; Ma J; Wang X; Liang X; Qi X; Yu B; Yang J
Biochim Biophys Acta Gen Subj; 2024 Apr; 1868(4):130566. PubMed ID: 38244703
[TBL] [Abstract][Full Text] [Related]
10. Ribonucleotide reductase subunit M1 assessed by quantitative double-fluorescence immunohistochemistry predicts the efficacy of gemcitabine in biliary tract carcinoma.
Nakamura J; Kohya N; Kai K; Ohtaka K; Hashiguchi K; Hiraki M; Kitajima Y; Tokunaga O; Noshiro H; Miyazaki K
Int J Oncol; 2010 Oct; 37(4):845-52. PubMed ID: 20811706
[TBL] [Abstract][Full Text] [Related]
11. Development of Patient-Derived Gastric Cancer Organoids from Endoscopic Biopsies and Surgical Tissues.
Gao M; Lin M; Rao M; Thompson H; Hirai K; Choi M; Georgakis GV; Sasson AR; Bucobo JC; Tzimas D; D'Souza LS; Buscaglia JM; Davis J; Shroyer KR; Li J; Powers S; Kim J
Ann Surg Oncol; 2018 Sep; 25(9):2767-2775. PubMed ID: 30003451
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
Tan ES; Cao B; Kim J; Al-Toubah TE; Mehta R; Centeno BA; Kim RD
Cancer; 2021 Apr; 127(8):1293-1300. PubMed ID: 33289918
[TBL] [Abstract][Full Text] [Related]
13. Targeted deep sequencing contributes to guiding personalized targeted therapy for advanced biliary tract cancer patients with non‑radical resection: A real‑world study.
Feng F; Cheng Q; Zhang D; Li B; Qin H; Xu C; Han M; Yu Y; Li Z; Li JY; Qiu Z; Xiong L; Liu C; Li F; Yi B; Jiang X
Oncol Rep; 2020 Apr; 43(4):1089-1102. PubMed ID: 32323774
[TBL] [Abstract][Full Text] [Related]
14. Establishment and drug screening of patient-derived extrahepatic biliary tract carcinoma organoids.
Wang Z; Guo Y; Jin Y; Zhang X; Geng H; Xie G; Ye D; Yu Y; Liu D; Zhou D; Li B; Luo Y; Peng S; Li J
Cancer Cell Int; 2021 Oct; 21(1):519. PubMed ID: 34600546
[TBL] [Abstract][Full Text] [Related]
15. Transgelin-2, a novel cancer stem cell-related biomarker, is a diagnostic and therapeutic target for biliary tract cancer.
Jo JH; Park SB; Chung J; Oh T; Lee HS; Chung MJ; Park JY; Bang S; Park SW; Jung DE; Song SY
BMC Cancer; 2024 Mar; 24(1):357. PubMed ID: 38509504
[TBL] [Abstract][Full Text] [Related]
16. Patient-derived functional organoids as a personalized approach for drug screening against hepatobiliary cancers.
Li L; Selaru FM
Adv Cancer Res; 2022; 156():319-341. PubMed ID: 35961704
[TBL] [Abstract][Full Text] [Related]
17. Patient-derived cancer organoids for drug screening: Basic technology and clinical application.
Ren X; Chen W; Yang Q; Li X; Xu L
J Gastroenterol Hepatol; 2022 Aug; 37(8):1446-1454. PubMed ID: 35771719
[TBL] [Abstract][Full Text] [Related]
18. Prognostic and predictive factors for Taiwanese patients with advanced biliary tract cancer undergoing frontline chemotherapy with gemcitabine and cisplatin: a real-world experience.
Wu CE; Chou WC; Hsieh CH; Chang JW; Lin CY; Yeh CN; Chen JS
BMC Cancer; 2020 May; 20(1):422. PubMed ID: 32410631
[TBL] [Abstract][Full Text] [Related]
19. Single-institution experience with gemcitabine-cisplatin combination therapy as a second-line treatment for patients with unresectable biliary tract cancer after failure of gemcitabine-S-1 combination therapy: a prospective feasibility study.
Matsuyama R; Morioka D; Mori R; Hiratani S; Yabushita Y; Ota Y; Kumamoto T; Taniguchi K; Endo I
Cancer Chemother Pharmacol; 2018 May; 81(5):949-955. PubMed ID: 29594362
[TBL] [Abstract][Full Text] [Related]
20. Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance.
Ahn DH; Javle M; Ahn CW; Jain A; Mikhail S; Noonan AM; Ciombor K; Wu C; Shroff RT; Chen JL; Bekaii-Saab T
Cancer; 2016 Dec; 122(23):3657-3666. PubMed ID: 27495988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
